Media

Fem Med Formulas announces an exclusive license agreement with NewBridge Pharmaceuticals

Fem Med Formulas announces an exclusive license agreement with NewBridge Pharmaceuticals

femMED health supplements for women will now be available in the Middle East, Turkey and Caspian Regions Dubai, UAE: 26 November 2013 - Women in several other parts of the world will soon have access to femMED products, a Canadian-based line of natural women’s health supplements for a wide variety ...

NEWBRIDGE ANNOUNCES PARTNERSHIP WITH EISAI TO MARKET BREAST CANCER TREATMENT HALAVENĀ® (ERIBULIN) ACROSS THE MIDDLE EAST

NEWBRIDGE ANNOUNCES PARTNERSHIP WITH EISAI TO MARKET BREAST CANCER TREATMENT HALAVENĀ® (ERIBULIN) ACROSS THE MIDDLE EAST

Dubai, UAE: 18 November 2013 – Eisai announces today that Halaven® (eribulin) will be marketed in selected countries within the Middle East region through a new partnership between Eisai EMEA (Europe, the Middle East, Africa, Russia and Oceania) and NewBridge Pharmaceuticals. Eribulin is indicated for the treatment of locally advanced or metastatic ...

NewBridge Pharmaceuticals secures significant investment from Elan, boosting growth and expansion

NewBridge Pharmaceuticals secures significant investment from Elan, boosting growth and expansion

Elan Corporation, plc. invests $40 million of a $48M Series C financing in NewBridge Pharmaceuticals and becomes a major shareholder alongside Burrill & Company and Kuwait Life Sciences Company. Dubai, UAE: 29 May 2013: NewBridge Pharmaceuticals  announced the close of a $48 million Series C equity fundraising with an outsized ...

NewBridge Pharmaceuticals secures significant investment from Elan, boosting growth and expansion

NewBridge Pharmaceuticals secures significant investment from Elan, boosting growth and expansion

Elan Corporation, plc. invests $40 million of a $48M Series C financing in NewBridge Pharmaceuticals and becomes a major shareholder alongside Burrill & Company and Kuwait Life Sciences Company. Dubai, UAE: 29 May, 2013: NewBridge Pharmaceuticals  announced the close of a $48 million Series C equity fundraising with an outsized ...

NewBridge Pharmaceuticals secures significant investment from Elan, boosting growth and expansion

NewBridge Pharmaceuticals secures significant investment from Elan, boosting growth and expansion

NewBridge Pharmaceuticals announced the close of a $48m Series C equity fundraising with an outsized investment of $40m from the Irish corporation, Elan, to expand its commercial and manufacturing operations in the Africa, Middle East and Turkey territories (AfMET).   The AfMET region's healthcare sector is rapidly expanding and evolving, ...

Page 1 of 3 1 2 3 »